All In Biotech

Drug Trial Radar · NCT00129922

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Phase III Study to Compare 6 Courses of FEC (Fluorouracil, Epirubicin and Cyclophosphamide) vs. 4 Courses of FEC Followed by 8 Weekly Paclitaxel Administrations, as Adjuvant Treatment for Node Positive Operable BC Patients

Last checked: Nov 20, 2026Latest source record: Mar 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,289 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,289

Actual

Start

Nov 1999

Primary completion

Dec 2005

Study completion Dec 2007

Sponsor

Lead sponsor
Spanish Breast Cancer Research GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bristol-Myers Squibb; Pfizer; Hoffmann-La Roche
First posted
Aug 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The efficacy of adjuvant chemotherapy is limited in patients with a high risk of recurrence. Also, for axillary positive node patients, optimum chemotherapy regimens are still under discussion. Some previous studies suggest that, in the subset of node-positive patients, treatments based on sequential administration of anthracyclines and taxanes are more efficient. Paclitaxel dose-dense (weekly) administration renders an improved therapeutic index (activity/toxicity). The study is designed to compare 6 courses of FEC scheme (600/90/600), a combination of proven efficacy in node positive breast cancer patients, versus 4 FEC courses followed by 8 weekly paclitaxel administrations (100mg/m2). The study hypothesis is that 5-year disease-free survival in the control arm will be 60%. The investigators expect to increase this by 8% with the experimental treatment. With an alpha error of 0.05, 80% power, and a post-randomization estimated drop-out rate of 10%, 1250 patients are needed, 625 per arm.

Conditions

  • Breast Cancer

Interventions

  • paclitaxelDrug

  • FluorouracilDrug

  • EpirubicinDrug

  • CyclophosphamideDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. disease-free survivalTime frame: 5 years

Locations

64 sites in 1 country. Site status is shown where the registry gives one.

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, Spain

  • Centro Oncológico de Galicia

    A Coruña, Spain

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital del Mar

    Barcelona, Spain

  • Clínica Oncológica Corachán

    Barcelona, Spain

  • Hospital Clinic i Provincial

    Barcelona, Spain

  • Hospital Universitario Puerta del Mar

    Cadiz, Spain

  • Hospital General Universitario de Ciudad Real

    Ciudad Real, Spain

  • Hospital Provincial de Córdoba

    Córdoba, Spain

  • Hospital General Universitario de Guadalajara

    Guadalajara, Spain

  • Hospital Juan Ramón Jiménez

    Huelva, Spain

  • Complejo Hospitalario de Jaén

    Jaén, Spain

  • Hospital de León

    León, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Spain

  • Hospital Clínico Universitario San Carlos

    Madrid, Spain

  • Hospital Clínico Unviersitario Virgen de la Victoria

    Málaga, Spain

  • Hospital General Universitario Morales Meseguer

    Murcia, Spain

  • Complejo Hospitalario de Ourense

    Ourense, Spain

  • Hospital Rio Carrión

    Palencia, Spain

  • Hospital Unviersitario de Salamanca

    Salamanca, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Spain

  • Hospital Virgen de la Salud

    Toledo, Spain

  • Hospital Provincial de Toledo

    Toledo, Spain

  • Hospital Universitario La Fe

    Valencia, Spain

  • Instituto Valenciano de Oncología

    Valencia, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Spain

  • Hospital General Universitario de Valencia

    Valencia, Spain

  • Hospital Universitario Arnau de Vilanova de Valencia

    Valencia, Spain

  • Hospital Universitario Dr. Peset

    Valencia, Spain

  • Hospital Clínico Universitario de Valladolid

    Valladolid, Spain

  • Hospital Provincial de Zamora

    Zamora, Spain

  • Hospital Clínico Universitario de Zaragoza "Lozano Blesa"

    Zaragoza, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, Spain

  • Hospital de Txagorritxu

    Vitoria-Gasteiz, Álava, Spain

  • Hospital Universitario Virgen de los Lirios

    Alcoy, Alicante, Spain

  • Hospital General Universitario de Elche

    Elche, Alicante, Spain

  • Hospital General Universitario de Elda

    Elda, Alicante, Spain

  • Hospital Municipal de Badalona

    Badalona, Barcelona, Spain

  • Hospital Unviersitario Germans Trias i Pujol

    Badalona, Barcelona, Spain

Showing 40 of 64 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.